A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia

Overview of attention for article published in PLOS ONE, October 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

So far, Dimensions has found 11 publications that cite this research output.

Article in RSC Advances (February 2024)

Article in Scientific Reports (May 2023)

Article in Annals of Hematology (November 2022)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.